Hartley said gross profit was negatively impacted by $1.9 million in one-time costs in the fourth quarter associated with the BLA approval, two-thirds of which were non-cash stock-based compensation tied to milestone vesting. Excluding one-time items, she attributed margin pressure mainly to higher product costs related to additional testing steps as Avance transitioned to a biologic, partially offset by fewer inventory write-offs and lower shipping costs following the case stock program’s discontinuation.G ...

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial Results Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the thir ...

Principal Financial Group Inc. raised its holdings in AxoGen, Inc. (NASDAQ:AXGN – Free Report) by 69.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,130 shares of the medical equipment provider’s stock after acquiring an additional 21,002 shares during the quarter. Principal Financial Group Inc. owned approximately 0.11% of AxoGen worth $912,000 as of its most recent filing with the Securities & Exchange Commission. Get AxoGen aler ...

Core Viewpoint - Axogen, Inc. is set to release its financial results for Q4 and the full year 2025 on February 24, 2026, followed by a conference call for the investment community [1]. Company Overview - Axogen, Inc. is a leader in developing and marketing surgical solutions aimed at restoring peripheral nerve function, with a mission to establish nerve repair as the standard of care [3]. - The company focuses on the science, development, and commercialization of technologies for peripheral nerve repair, collaborating with surgeons and healthcare providers globally [3]. Product Portfolio - Axogen's product offerings include: - Avance® (acellular nerve allograft-arwx) - Avance® Nerve Graft - Axoguard Nerve Connector® - Axoguard Nerve Protector® - Axoguard HA+ Nerve Protector™ - Axoguard Nerve Cap® - Avive+ Soft Tissue Matrix™ [4].

Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].

Core Viewpoint - Axogen, Inc. plans to offer and sell $85.0 million of its common stock in a proposed underwritten public offering, with an additional option for underwriters to purchase up to $12.75 million more [1][2] Group 1: Offering Details - The proposed offering is subject to market conditions and other factors, with no assurance on the completion or terms of the offering [1] - Wells Fargo Securities and Mizuho are the lead book-running managers, while Canaccord Genuity and Raymond James are co-managers for the offering [2] - The offering is made under an automatic shelf registration statement that became effective upon filing with the SEC on January 21, 2026 [3] Group 2: Use of Proceeds - Axogen intends to use the net proceeds from the offering for early payoff and termination of its term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [2] Group 3: Company Overview - Axogen focuses on the science, development, and commercialization of technologies for peripheral nerve repair, aiming to make nerve repair the expected standard of care [5] - The company's product portfolio includes various nerve repair solutions such as Avance® nerve grafts and Axoguard® products [6]

Financial Performance - Q3 2025 revenue increased to $60.1 million, a 23.5% year-over-year growth[11] - Net income for Q3 2025 was $0.7 million, compared to a loss of $1.9 million in Q3 2024[22] - Adjusted EBITDA for Q3 2025 was $9.2 million, with an Adjusted EBITDA margin of 15.4%[22] - Operational cash increased by $3.9 million, reaching $39.8 million as of September 30, 2025[24] Business Growth & Development - High Potential (HiPo) accounts contributed approximately 64% of year-over-year revenue growth[11] - HiPo accounts showed a 19% year-over-year increase in average account productivity[11] - The company trained 62 surgeon pairs in Breast procedures YTD, with 281 procedures performed in Q3, a 20% year-over-year increase[11] - The company trained 57 surgeons in OMF/H&N procedures YTD, exceeding the target of 45[11] - Approximately 1.1 million estimated additional covered lives were added in Q3, with approximately 18.1 million new lives YTD[13] Guidance - The company is raising guidance for the full year 2025, projecting revenue growth of at least 19%, or $222.8 million[26]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Axogen, Inc. and its officers or directors [1] Group 1: Company Developments - On August 25, 2025, Axogen announced that the FDA extended the PDUFA goal date for its Biologics License Application for Avance® Nerve Graft by three months to December 5, 2025 [3] - Following this announcement, Axogen's stock price decreased by $1.47 per share, or 9.04%, closing at $14.79 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Axogen for possible securities fraud or other unlawful business practices [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4]